Pelage Pharmaceuticals closed a $120 million Series B to advance its lead topical program PP405 for hair follicle stem cell reactivation. The round was co-led by ARCH Venture Partners and GV, with participation from Main Street Advisors, Visionary Ventures, and YK Bioventures.
Comments
Want to join the conversation?
Loading comments...